Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392)
Shanghai Stock Exchange · China · prices in CNY · close of 22 Oct 2026
Key indicators
| Last close | CNY 24.98 |
|---|---|
| 52-week range | 24.70 – 58.66 |
| Return, 1 month / 3 months | −4.7% / −15.0% |
| Return, 1 year / 3 years | −54.8% / −42.9% |
| Trend | Below its 200-day average |
| RSI (14) | 40 |
| Volatility (1 year) | 37.0% |
| Worst drawdown (1 year) | -57.0% |
| Average daily value traded | 191.25M CNY |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Beijing Wantai Biological Pharmacy Enterprise develops and manufactures diagnostic test kits and vaccines. Its diagnostics cover infectious diseases and blood screening, using laboratory and rapid test formats, and are supplied to hospitals, blood centres and public health programmes. The company also makes vaccines, including one against hepatitis E and one against human papillomavirus. It is based in Beijing, China, and serves healthcare providers and disease-control bodies in its home market and abroad.
On this site Beijing Wantai Biological Pharmacy Enterprise Co Ltd appears as a stock on the Shanghai Stock Exchange (China), code 603392, with prices in Chinese yuan (CNY). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Beijing Wantai Biological Pharmacy Enterprise Co Ltd (603392) trades on the Shanghai Stock Exchange in China. It last closed at CNY 24.98 on 22 October 2026.
Its price-based Market X-Ray is 28 out of 100 (a weak price profile), ranking 2,047 of 2,278 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 54.8% and over the last three months it fell 15.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Shanghai Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 12 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -28.9% | ||
| From 52-week high | -55.7% | ||
| Momentum | 10 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -15.0% | ||
| 6-month return | -35.8% | ||
| 12-month return, skipping the last month | -52.6% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 37.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -57.0% | ||
| Liquidity | 61 · Fair | Moderate trading activity. | |
| Average daily value traded | 191.25M CNY | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −1.3% |
|---|---|
| 1 month | −4.7% |
| 3 months | −15.0% |
| 6 months | −35.8% |
| 1 year | −54.8% |
| 3 years | −42.9% |
| 5 years | −77.2% |
Signals
| 50-day / 200-day average | 27.67 / 35.12 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.89 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 Jun 2023 | CNY 1.4000 |
| 21 Apr 2022 | CNY 0.2900 |
| 18 May 2021 | CNY 0.3500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Shanghai Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.